Tailored solution for people with Parkinson’s disease
NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families.
NeuroDerm’s uniqueness lies in integrating diverse capabilities into a comprehensive solution for the benefit of patients and the future of healthcare and healthcare connectivity.
NeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations.
Our system for self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa, was designed specifically to be a user-friendly system for people with Parkinson's disease, to maintain steady therapeutic levodopa plasma concentrations for the purpose of improving fluctuations, that is, reducing patients’ "OFF" time without increasing troublesome dyskinesia.
Our tailored solution potentially offers sustained relief (compared to oral immediate-release levodopa/carbidopa treatments) and empowers patients and their families to regain control of their lives with greater daily-life predictability and independence.
ND0612 has successfully completed Phase I and II clinical trials and is currently recruiting patients for a Phase III efficacy study. The BeyoND pivotal study was designed to evaluate the long-term safety of ND0612 and has been completed with over 4 years of accumulated long-term safety data.
The BouNDless pivotal study, designed to evaluate the efficacy of ND0612, is currently recruiting (click here to learn more).
NeuroDerm has completed 8 Phase-I and clinical pharmacology studies, ranging from small dose-finding studies to 12-month population pharmacokinetics studies.Learn More
Three completed Phase-II studies have established a robust platform of evidence supporting the safety, tolerability, and preliminary efficacy of ND0612 in people with Parkinson’s disease.Learn More
BouNDless Study - Still recruitingLearn More